Safety and efficacy of routine anticoagulation after primary PCI in STEMI: a systematic review and meta-analysis

Anika Chowdhury1, Dhruvkumar Arvindbhai Vasoya2, Mahfuja Jahan Ima3

  • 1Shaheed Suhrawardy Medical College and Hospital, Dhaka, 1207, Bangladesh.

Insights

Postprocedural anticoagulation (PPAC) after percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) did not reduce mortality or major adverse cardiovascular events. However, PPAC significantly increased the risk of bleeding events.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Clinical Trials

Background:

  • Percutaneous coronary intervention (PCI) is a key treatment for ST-elevation myocardial infarction (STEMI).
  • The role and effectiveness of postprocedural anticoagulation (PPAC) following PCI in STEMI patients remain debated.
  • This study evaluates the clinical outcomes associated with PPAC in STEMI patients undergoing PCI.

Purpose of the Study:

  • To assess the necessity and efficacy of postprocedural anticoagulation (PPAC) in STEMI patients after percutaneous coronary intervention (PCI).
  • To compare clinical outcomes, including mortality and adverse events, between PPAC and control groups.

Main Methods:

  • A systematic literature search was conducted across Embase, PubMed, and Clinicaltrials for relevant randomized controlled trials (RCTs).
  • Meta-analysis was performed using RevMan 5.4.1 with a random-effects model, calculating odds ratios (ORs) and 95% confidence intervals (CIs).
  • Risk of bias was assessed using Cochrane's RoB 2.0 tool.

Main Results:

  • The meta-analysis included 5 RCTs with 13,586 patients; 50.26% received PPAC.
  • PPAC did not significantly reduce all-cause mortality (OR 1.08), cardiovascular mortality (OR 1.08), MACE (OR 1.13), stent thrombosis (OR 1.07), or stroke (OR 1.50).
  • PPAC was associated with a significantly higher odds of bleeding (OR 1.78; P=0.03).

Conclusions:

  • Postprocedural anticoagulation (PPAC) following PCI for STEMI does not offer significant benefits in reducing mortality, MACE, stent thrombosis, or stroke.
  • PPAC is associated with an increased risk of bleeding complications.
  • Further RCTs are recommended to confirm these findings and guide clinical practice regarding PPAC in STEMI patients.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
28
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
32
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
48
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
655
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
81
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
39